You are here: Industry Insights > Diabetes

News List

ViaCyte, Gore to Develop Technologies that Enhance Delivery of Therapies for Diabetes americanpharmaceuticalreview
March 05, 2021
ViaCyte and W. L. Gore & Associates announced the two companies have signed an expanded joint development agreement covering the development and use of proprietary Gore materials and device capabilities to further optimize ViaCyte's portfolio of ...
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn pharmaceutical-technology
March 02, 2021
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma for JPY133bn ($1.25bn).
Sciwind's Investigational New Drug Approved for NASH Trial prnasia
March 01, 2021
Hangzhou Sciwind Biosciences Co., Ltd. today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.
Gan & Lee Announces New Partnership with International Diabetes Federation prnasia
February 22, 2021
Gan & Lee Pharmaceuticals Co., Ltd. has announced a collaborative partnership with the International Diabetes Federation (IDF) that aims to support their global efforts of promoting diabetes care and prevention worldwide.
Metavention Initiates Trial for Novel Treatment of Type 2 Diabetes americanpharmaceuticalreview
February 20, 2021
Metavention announced the initiation of an U.S. Food and Drug Administration (FDA) approved clinical investigation, DeLIVER, for the Company's intravascular iRF Denervation System to determine safety in patients with type 2 diabetes (T2D).
Biocon Biologics partners with IDF to improve access to insulins expresspharma
February 18, 2021
Biocon Biologics, a subsidiary of Biocon, has announced a partnership with the International Diabetes Federation (IDF) to promote and support IDF’s Core Mission initiative and activities.
UK researchers find semaglutide could be a ‘game changer’ drug to fight obesity expresspharma
February 18, 2021
The drug, semaglutide, works by hijacking the body's own appetite-regulating system in the brain leading to reduced hunger and calorie intake, according to the study.
ViaCyte Announces Initiation of Encapsulated Cell Therapy Study for Type 1 Diabetes americanpharmaceuticalreview
February 08, 2021
ViaCyte announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 clinical study utilizing encapsulated delivery of cells.
Creative Medical Technology Announces Positive Data Using ImmCelz to Treat Type 1 Diabetes americanpharmaceuticalreview
January 20, 2021
Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz? in prevention and regression of type 1 diabetes.
Metformin use reduces risk of death for patients with COVID-19 and diabetes worldpharmanews
January 19, 2021
Use of the diabetes drug metformin - before a diagnosis of COVID-19 - is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at the University of Alabama at Birmingham ...